Revenue, 2025

USD 16.05 Billion

Forecast, 2035

USD 129.61 Billion

CAGR, 2026-2035

23.23%

Report Coverage

Global

Biosimilar Monoclonal Antibodies Market Trends for 2026

The global biosimilar monoclonal antibodies market size was estimated at USD 16.05 billion in 2025 and is predicted to increase from USD 19.78 billion in 2026 to approximately USD 129.61 billion by 2035, expanding at a CAGR of 23.23% from 2026 to 2035.

The biosimilar monoclonal antibodies market is growing due to increasing applications of these antibodies in oncology autoimmune and inflammatory diseases, ophthalmology, and other areas.

Key Takeaways

• Biosimilar monoclonal antibodies sector pushed the market to USD 19.78 billion by 2026.
• Long-term projections show USD 129.61 billion valuation by 2035.
• Growth is expected at a steady CAGR of 23.23% in between 2026 to 2035.
• North America dominated the biosimilar monoclonal antibodies market by 41% share in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By type, the infliximab segment dominated the market share of 26% in 2025.
• By type, the adalimumab segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By indication, the oncology segment accounted for the largest biosimilar monoclonal antibody market share of 48% in 2025, and is expected to register the highest CAGR during the forecast period.
• By end-user, the hospital segment accounted for the largest share of 62% in 2025, and is expected to register the highest CAGR during the forecast period.

Market Overview: What are Biosimilar Monoclonal Antibodies?

The biosimilar monoclonal antibodies market is growing due to growing access and lower expenses for patients and medical care systems.  Monoclonal antibodies (mAbs) are a main class of recombinant deoxyribonucleic acid (rDNA) technology-based biotherapeutic products that attain outstanding achievement in treating many life-threatening and long-term diseases such as cancer, rheumatoid arthritis, and autoimmune disease. Biosimilar antibodies make it possible to research the biological effects of a drug without requiring the sourcing of expensive pharmaceutical-grade therapeutics.

What is the Role of AI in the Market?

AI is transforming the biosimilar monoclonal antibodies market by accelerating R&D, significantly reducing development timelines and costs. Machine learning models optimize antibody characterization, predict structural similarities to reference products, and enhance manufacturing processes. AI-driven predictive analytics minimize manufacturing waste, ensure consistent quality, and assist in regulatory compliance. Furthermore, AI helps in navigating market penetration, making biosimilars more affordable and accessible, thereby enhancing market competition and patient access.

Future Outlook & Trends in the Biosimilar Monoclonal Antibodies Market

Advanced Antibody Engineering:

Antibody engineering allows the manufacturing of antibodies with high specificity, stability, affinity, and low immunogenicity, while also engineering new functionalities beyond those of natural antibodies, therefore increasing their uses in disease treatment and diagnostics.

Next-Gen Sequencing (NGS):

Next-generation sequencing (NGS) provides an affordable service with increased read depth, enabling an inclusive understanding of diversity.

Multispecific Antibodies:

Multispecific antibodies are evolved to engage two or more different targets, offering medicinal advantages over conventional monoclonal antibodies. These include improved recruitment of immune effector cells, concurrent modulation of multiple signalling pathways, and introduction of apoptosis.

Quick Facts Table

Segmentation Analysis

By Type Insights

Which Type Led the Biosimilar Monoclonal Antibodies Market in 2025?

In 2025, the infliximab segment held the dominant market share by 26%, as it is applied alone or in combination with other various treatments to lower the symptoms and prevent the progression of moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, and active ankylosing spondylitis. It works to boost and improve the immune system. The efficiency of infliximab demonstrated the practicality of monoclonal antibody therapies in targeting specific molecules involved in disease pathology.

Adalimumab

Whereas the adalimumab segment is the fastest-growing in the market, as these are used to lessen swelling by working on the immune system. Adalimumab is applied to treat inflammation of the joints, such as rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and active enthesitis-related arthritis, and skin conditions such as plaque psoriasis and hidradenitis suppurativa. Adalimumab efficiently reduces inflammation, averts tissue damage, and progresses disease management, leading to better long-term results for patients.

Indication Insights

Why did the Oncology Segment Dominate the Market in 2025?

The oncology segment is dominant in the biosimilar monoclonal antibodies market by 48% share in 2025, and is expected to register the highest CAGR during the forecast period, as it has massive strength advantages in managing cancer. They introduce competition into the drug development process, which leads to investment savings for patients and accelerates the development of novel treatments.

By End User Insights

Why did the Hospital Segment Dominate the Market in 2025?

The hospital segment is dominant in the biosimilar monoclonal antibodies market by 62% in 2025 and is expected to register the highest CAGR during the forecast period, as biosimilar monoclonal antibodies present a significant advancement in aligning medical care innovation with medical care affordability. Investigators use mAbs (biosimilars) as tools to research novel therapies and uncover efficacy in off-target applications. Biosimilars provide affordable treatment options that support contain the in-healthcare expenditure.

Regional Insights

How did North America Dominate the Market in 2025?

In 2025, North America led the biosimilar monoclonal antibodies market with share of 41%, as the growing prevalence of long term diseases like cancer and autoimmune disorders, and increasing demand for personalized medicine and targeted therapy. The FDA has approved 76 biosimilars, corresponding to a small fraction of approved biologics. There are more than 30,000 approved generics, increasing the number of approved brand drugs, which drives the growth of the market.

For Instance,

• In April 2025, Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that the U.S. Food and Drug Administration had approved Jobevne, a biosimilar of Bevacizumab for intravenous use.

U.S. Market Trends

In the U.S. presence of significant pharmaceutical organizations such as Pfizer, Amgen, and Sandoz is headquartered or heavily active in this region, increasing product advancement and introductions.  Development in mAb technology is increasing advances in oncology, autoimmune disorders, and infectious diseases. Around 6 in 10 Americans live with at least one chronic disease, with cardiac disease and diabetes, which increases the need for biosimilar monoclonal antibodies.

Asia Pacific: Growing Healthcare Spending

Asia Pacific is set to experience rapid growth in the biosimilar monoclonal antibodies market by 20% share, as Asia accounts for 22% of worldwide healthcare investment, with chronic conditions like diabetes and cancer disproportionately affecting the region, which drives the growth of the market. Increasing government support, such as South Korea's Ministry of Health and Welfare (MOHW), will implement the Pharmaceutical Pricing System Improvement Plan.

For Instance,

• In October 2026, Takeda announced that it had entered into a license and collaboration agreement with Innovent Biologics for the development, production, and commercialization of two late-stage oncology medicines, IBI363 and IBI343, outside of Greater China.

India Market Trends

The Indian government has set a minimum import price (MIP) for some key pharmaceutical inputs to combat aggressive undercutting and dumping from Chinese manufacturers, which increases the demand for biosimilar monoclonal antibodies.

Europe: Presence of Advanced Healthcare System

Europe is experiencing substantial growth in the biosimilar monoclonal antibodies market by 29% share, as biosimilars continue to be an important part of the European medical system, and it balances pharmaceutical investment by creating savings for payers, generating headroom for novelty, and increasing access to biologic therapy for patients, which drives the growth of the market.

UK Market Trends

The UK has a significant integration of proactive regulatory streamlining (MHRA), strong NHS-led cost-containment and advance approches, enhance physician confidence, and leveraging post-Brexit government autonomy. NHS England is targeting £150 million in savings via the rapid adoption of biosimilar adalimumab.

How is the Market Growing in the South American Region?

The market in South America is rapidly growing due to patent expirations for major biologics, a demand for affordable chronic illness treatments, and government cost-control initiatives. Streamlined regulations, increased physician confidence in biosimilars, and enhanced local manufacturing are accelerating growth. The rise in cancer and autoimmune diseases is driving the need for cost-effective therapies like rituximab, trastuzumab, and adalimumab. Public health systems favor tender-based purchasing, promoting cheaper biosimilars over expensive originals. Investments in biotechnology and partnerships between local and international firms are enhancing regional manufacturing.

Brazil Market Trends

Brazil is the leader in the Latin American market, fueled by high public health demand, government strategies for local production, and a robust regulatory framework from ANVISA. The SUS oversees most biological products, steering the market towards affordable biosimilars, often influenced by legal challenges over high medication costs. Public-private partnerships (PPPs) between state-owned and private companies bolster local manufacturing and technology transfer, crucial for market dominance. Local companies like Blau Farmacêutica have successfully created advanced biosimilars, such as pembrolizumab. Brazil is the primary growth engine for Latin America's biologics market due to its infrastructure, economic scale, and strategic advantages.

How is the Market Growing in the MEA Region?

The biosimilar monoclonal antibodies market in the Middle East and Africa is expanding by 4% share due to the need for affordable chronic illness treatments, increased healthcare spending, and supportive regulations. Key drivers include rising cancer and autoimmune disease rates, patent expirations on major biologics, and the demand for cost-effective alternatives to improve patient access. The growing number of patients with cancer and chronic conditions like diabetes and arthritis heightens the demand for affordable biologic therapies. Biosimilars offer significant savings over branded biologics, helping to lower healthcare costs. The expiration of patents on expensive monoclonal antibodies allows for the introduction of more affordable biosimilars, while improved healthcare infrastructure and a focus on biotechnology support local production and acceptance.

UAE Market Trends

In the UAE, the market is shaped by a high incidence of chronic diseases, a demand for cost-effective treatments, and strong government support for biotechnology. Factors include advanced healthcare systems in Dubai and Abu Dhabi, quick regulatory approvals, and increased local manufacturing investment. The rise in cancer and autoimmune diseases drives the need for affordable biologics, with biosimilars providing economical alternatives that enhance healthcare sustainability and patient access. Supportive policies, such as fast-tracked regulatory approvals and local production investments, further boost the market, positioning the UAE as a key pharmaceutical hub in the MENA region.

Value Chain Analysis-Biosimilar Monoclonal Antibodies Market

R&D:

• R&D processes involve such tasks as target selection and reference product analysis, upstream process development, downstream process development, stepwise comparability assessment, and healthcare advancement.
• Key Players: Samsung Bioepis and Biocon Biologics Inc.

Manufacturing Processes:

• It involves significant manufacturing processes such as upstream processing, downstream processing, formulation, fill, and finish, critical quality control, and comparability.
• Key Players: Sandoz and Pfizer Inc.

Patient Services:

• Biosimilar monoclonal antibodies (mAbs) majorly focus on growing accessibility, cost-effectivity, and education to mirror the support provided by brand-name biologics.
• Key Players: Amgen Inc. and Celltrion Healthcare

Latest Updates of Key Players in the Biosimilar Monoclonal Antibodies Market

SWOT Analysis

Strengths

• Biosimilars are less expensive than originator biologic agents because biosimilars do not have to undertake the intensive clinical advancement process regarding approval of an originator.
• Biosimilar mAbs are therapeutics for treatments of autoimmune diseases. Biologics have transformed the treatment of immune-based inflammatory diseases.

Weakness

• The main complexities raised related to biosimilars are immunogenicity, efficacy, side effects when switching from a biologic to a biosimilar, and possible long-term effects.

Opportunities

• AI-based drug design and bioinformatics are being combined to speed up biosimilar characterization and ensure higher structural similarity to reference products.
• The future of monoclonal antibody therapies is hopeful, with advancements such as bispecific antibodies and CAR-T cell therapies evolving. These innovations enales for more targeted treatment choices that target various pathways simultaneously.

Threat

• Major challenge for the production of mAbs, and for biopharmaceuticals in general, with high related costs in resource and animal use.

Recent Developments in the Biosimilar Monoclonal Antibodies Market

• In November 2025, Sandoz announced that TYRUKO is available to patients in the US. Developed by Polpharma Biologics, TYRUKO is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).
• In October 2025, Leinco Technologies is proud to announce the launch of its novel AI-based tool, the Leinco Antibody Advisor. This innovative feature is designed to enhance customer support by providing on-demand answers to frequently asked questions about Leinco’s products.

Segments Covered in the Report

By Type

• Adalimumab
• Bevacizumab
• Infliximab
• Rituximab
• Trastuzumab
• Others

By Indication

• Oncology
• Autoimmune diseases
• Others

By End User

• Hospitals
• Cancer treatment centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait